Bulk Pharmaceutical API Sources for BREXPIPRAZOLE

Bulk Pharmaceutical API Sources for BREXPIPRAZOLE

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-2108
MedChemexpress MCE		HY-15780
AKos Consulting & Solutions		AKOS025291100

Bulk API Sources for Brexpiprazole

Last updated: February 20, 2026

Brexpiprazole (brand name Rexulti) is a serotonin-dopamine activity modulator used for schizophrenia and major depressive disorder. The production of bulk active pharmaceutical ingredient (API) for brexpiprazole involves specialized manufacturing facilities compliant with Good Manufacturing Practices (GMP).

Leading API Suppliers for Brexpiprazole

Most commercially available brexpiprazole APIs are produced by a limited number of manufacturers. These companies operate globally, primarily in Asia and North America.

Major API Manufacturers

Company Name	Location	Certification	Capacity (Estimated)	Notes
ChemCon GmbH	Germany	GMP, ISO 9001	Moderate	Supplies APIs for specialty drugs, including brexpiprazole.
Jiangsu Hengrui Medicine Co.	China	GMP, ISO 13485	Large	One of China’s top pharmaceutical exporters, involved in API production for psychiatric drugs.
Jiangxi Holin Pharmaceutical	China	GMP	Moderate	Focuses on psychiatric API manufacturing.
Dr. Reddy's Laboratories	India	GMP, ISO 9001	Large	Produces APIs for global markets, including specialty compounds.
Hetero Labs	India	GMP	Moderate	Offers a range of APIs, including neuropsychiatric drugs.

Source Quality Standards

Manufacturers comply with international standards such as:

• Good Manufacturing Practices (GMP) by FDA, EMA, and local authorities.
• ISO certifications depending on supply chain requirements.
• Data transparency varies; most suppliers do not publicly disclose detailed batch data or capacity.

Supply Chain Dynamics

• API supply is concentrated in China and India, with specialty API manufacturers in Europe.
• Capacity constraints exist, especially for high-demand APIs like brexpiprazole.
• Some suppliers may license patents or proprietary synthesis routes from originators such as Otsuka Pharmaceutical.

API Synthesis and Quality Control

Brexpiprazole API synthesis involves multi-step chemical processes, including:

• Chiral synthesis to achieve stereochemically pure compounds.
• Use of specific reagents and catalysts with strict impurity controls.
• Validation of APIs via HPLC, LC-MS, and NMR to confirm purity (>99%) and batch consistency.

Quality control parameters determine API suitability:

• Assay (purity): ≥ 99%
• Impurities: ≤ 0.5%
• Residual solvents and heavy metals: within pharmacopeia limits.

Manufacturers must demonstrate stability, solubility, and bioavailability standards to clients.

Regulatory and Export Considerations

API suppliers targeting global markets must align with regulatory standards, including:

• GMP compliance required for export licenses.
• Certification for regulatory submission in key markets such as the US (FDA), EU (EMA), and China (NMPA).

Some providers may require confidentiality agreements due to proprietary synthesis routes and undisclosed intermediates.

Market Challenges and Trends

• API manufacturing is affected by geopolitical trade policies.
• COVID-19 disrupted supply chains, leading to calls for diversification.
• Increasing demand for high-quality, low-impurity APIs heightens the need for advanced synthesis processes.

Companies are investing in process optimization and capacity expansion to meet global demand for brexpiprazole API.

Summary of API Procurement Strategies

• Direct sourcing from OEMs with GMP-certified facilities.
• Engaging regional distributors for timely supply.
• Entering licensing agreements with patent holders or authorized API manufacturers.

Key Takeaways

• Brexpiprazole API is predominantly produced by companies in China and India.
• Quality standards align with international GMP regulations, ensuring batch consistency and purity.
• Supply chain constraints persist, impacting global availability.
• Regulatory compliance is essential for export, requiring GMP certification and detailed documentation.
• The market trend favors capacity expansion and process innovation to meet rising demand.

FAQs

1. Who are the primary API suppliers for brexpiprazole?

Mostly Chinese and Indian manufacturers, including Jiangsu Hengrui, Jiangxi Holin, Dr. Reddy’s, and Hetero Labs.

2. What quality standards do API suppliers need to meet?

GMP certification, with batch purity ≥99%, low impurity levels, and compliance with pharmacopeia requirements.

3. How does API synthesis for brexpiprazole work?

A multi-step process involving stereoselective reactions, purification steps, and rigorous quality control testing.

4. What are key regulatory considerations for API procurement?

Manufacturers must hold GMP certificates approved by relevant authorities; documentation must comply with regional regulations for export.

5. Are there capacity limitations for brexpiprazole API?

Yes, supply chain disruptions and high demand can cause capacity constraints, especially among smaller regional suppliers.

---

References:

1. World Health Organization. (2021). GMP guidance documents. Retrieved from WHO website.
2. US Food and Drug Administration. (2022). GMP regulations for finished pharmaceuticals. FDA.
3. China National Medical Products Administration. (2021). Drug registration and API manufacturing guidelines. NMPA.
4. International Institute for Sustainable Development. (2020). API manufacturing standards in Asia. IISD.